Join the Crohn's Disease group to help and get support from people like you.
Crohn's Disease News (Page 3)
Related terms: Crohns
ACG: Intestinal Ultrasound Monitoring Cuts Time to Treatment Change in IBD
WEDNESDAY, Oct. 25, 2023 – For patients with inflammatory bowel disease (IBD), monitoring by intestinal ultrasound (IUS) results in reduced time to treatment change and to remission, according to a...
COVID Might Raise Odds for Immune Disorders Like Crohn's, Alopecia
TUESDAY, Oct. 10, 2023 – In rare cases, some patients may develop an autoimmune disease following a bout of COVID, Korean researchers report. Conditions such as alopecia (hair loss), psoriasis,...
Autoimmune, Autoinflammatory Connective Tissue Disorders Increased After COVID-19
TUESDAY, Oct. 10, 2023 – COVID-19 is associated with an increased risk for autoimmune and autoinflammatory connective tissue disorders, according to a study published online Oct. 6 in JAMA Network...
FDA Grants Interchangeable Designation to Pfizer’s Biosimilar Abrilada
NEW YORK, October 5, 2023 – Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has designated Abrilada™ (adalimumab-afzb) as an interchangeable biosimilar to Hum...
Inflammatory Bowel Disease Tied to Higher Risk for Gout
TUESDAY, Oct. 3, 2023 – Inflammatory bowel disease (IBD) is strongly associated with gout, according to a study published online Sept. 1 in JGH Open. Osama Hamid, M.B.B.S., from the Cleveland...
FDA Approves Tyruko (natalizumab-sztn), a Biosimilar to Tysabri
August 24, 2023 – The U.S. Food and Drug Administration today approved Tyruko (natalizumab-sztn), the first biosimilar to Tysabri (natalizumab) injection for the treatment of adults with relapsing...
FDA Approves Yuflyma (adalimumab-aaty), a Biosimilar to Humira
JERSEY CITY, N.J.--(BUSINESS WIRE) May 24, 2023 --Celltrion USA today announced that the U.S. Food and Drug Administration (FDA) has approved Yuflyma® (adalimumab-aaty), a high-concentration ...
U.S. FDA Approves Rinvoq (upadacitinib) as a Once-Daily Pill for Moderately to Severely Active Crohn's Disease in Adults
NORTH CHICAGO, Ill., May 18, 2023 /PRNewswire/ – AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved Rinvoq® (upadacitinib) for the treatment of adults w...
Skyrizi (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults
Third approved indication for Skyrizi (risankizumab-rzaa) is supported by safety and efficacy data from two induction and one maintenance clinical trials evaluating Skyrizi in moderately to severely...
FDA Approves Yusimry (adalimumab-aqvh), a Biosimilar to Humira
REDWOOD CITY, Calif., Dec. 20, 2021 (GLOBE NEWSWIRE) – Coherus BioSciences, Inc. (Nasdaq: “CHRS”, “the Company”, “Coherus”) announced that the United States Food and Drug Administration (“FDA”) appro...
FDA Approves Hulio (adalimumab-fkjp), a Biosimilar to Humira
HERTFORDSHIRE, England and PITTSBURGH and TOKYO, July 9, 2020 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) and Fujifilm Kyowa Kirin Biologics Co., Ltd. today announced that the U.S. Food and Drug Admini...
FDA Approves Abrilada (adalimumab-afzb), a Biosimilar to Humira
November 18, 2019 - Pfizer Inc. (NYSE: PFE) today announced the United States (U.S.) Food and Drug Administration (FDA) has approved Abrilada™ (adalimumab-afzb), as a biosimilar to Humira® (a...
FDA Approves Hyrimoz (adalimumab-adaz), a Biosimilar to Humira
Holzkirchen, Germany, October 31, 2018 - Sandoz, a Novartis division and the pioneer and global leader in biosimilars, today announced that the US Food and Drug Administration (FDA) approved its...
FDA Approves Ixifi (infliximab-qbtx), a Biosimilar to Remicade
December 13, 2017 – Pfizer Inc. (NYSE:PFE) announced today that the United States (U.S.) Food and Drug Administration (FDA) has approved Ixifi (PF-06438179, infliximab-qbtx), a chimeric...
FDA Approves Cyltezo (adalimumab-adbm), a Biosimilar to Humira
Ridgefield, Conn., August 29, 2017 – Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved Cyltezo, a biosimilar to Humira, in a p...
Further information
Related condition support groups
Crohn's Disease - Maintenance, Inflammatory Bowel Disease
Related drug support groups
Humira, Remicade, Entyvio, Stelara, Skyrizi, cholestyramine, adalimumab, budesonide